Amneal (AMRX) Reports Q4 Earnings: What Key Metrics Have to Say

Amneal Pharmaceuticals (AMRX) reported $616.98 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 1.2$0.14 for the same period compares to $0.23 a year ago.The reported revenue compares to the Zacks Consensus Estimate of$630.67 million, representing a surprise of -2.17%. The company delivered an EPS surprise of +100.00%, with the consensus EPS estimate being $0.07.While investors scrutinize revenue and earnings changes year-over-year and how they com ...